Trial Profile
A Clinical Trial of JAK Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2024
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Muscle injury
- Focus Biomarker; First in man; Pharmacodynamics; Pharmacogenomic; Proof of concept
- 10 Apr 2024 Planned End Date changed from 16 May 2024 to 16 Nov 2024.
- 10 Apr 2024 Planned primary completion date changed from 16 May 2024 to 16 Nov 2024.
- 21 Nov 2023 Primary endpoint has been amended.